Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.
Redondo-Calvo FJ, Padín JF, Muñoz-Rodríguez JR, Serrano-Oviedo L, López-Juárez P, Porras Leal ML, González Gasca FJ, Rodríguez Martínez M, Pérez Serrano R, Sánchez Cadena A, Bejarano-Ramírez N, Muñoz Hornero C, Barberá Farré JR, Domínguez-Quesada I, Sepúlveda Berrocal MA, Villegas Fernández-Infantes MD, Manrique Romo MI, Parra Comino Á, Pérez-Ortiz JM, Gómez-Romero FJ; ATAC team.
Redondo-Calvo FJ, et al. Among authors: barbera farre jr.
Eur J Clin Invest. 2022 Jun;52(6):e13776. doi: 10.1111/eci.13776. Epub 2022 Apr 5.
Eur J Clin Invest. 2022.
PMID: 35342931
Free PMC article.
Clinical Trial.